114 related articles for article (PubMed ID: 3098689)
1. Surface markers of human lymphokine-activated killer cells and their precursors. Analysis at the population and clonal level.
Ferrini S; Moretta L; Pantaleo G; Moretta A
Int J Cancer; 1987 Jan; 39(1):18-24. PubMed ID: 3098689
[TBL] [Abstract][Full Text] [Related]
2. T cell nature of some lymphokine-activated killer (LAK) cells. Frequency analysis of LAK precursors within human T cell populations and clonal analysis of LAK effector cells.
Moretta L; Pende D; Cozzani R; Merli A; Bagnasco M; Mingari MC
Eur J Immunol; 1986 Dec; 16(12):1623-5. PubMed ID: 3102249
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.
Ferrini S; Miescher S; Zocchi MR; von Fliedner V; Moretta A
J Immunol; 1987 Feb; 138(4):1297-302. PubMed ID: 3100633
[TBL] [Abstract][Full Text] [Related]
4. Glycoproteic nature of surface molecules of effector cells with lymphokine-activated killer (LAK) activity. Evidence that T11, T8 or T3 molecules are not involved in tumor-cell lysis by LAK effector T cells.
Bagnasco M; Mingari MC; Pende D; Venuti D; Canonica GW; Moretta L
Int J Cancer; 1987 Jun; 39(6):703-7. PubMed ID: 3108168
[TBL] [Abstract][Full Text] [Related]
5. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors.
Rayner AA; Grimm EA; Lotze MT; Wilson DJ; Rosenberg SA
J Natl Cancer Inst; 1985 Jul; 75(1):67-75. PubMed ID: 2989604
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
Grimm EA; Ramsey KM; Mazumder A; Wilson DJ; Djeu JY; Rosenberg SA
J Exp Med; 1983 Mar; 157(3):884-97. PubMed ID: 6601174
[TBL] [Abstract][Full Text] [Related]
7. A novel 120-kD surface antigen expressed by a subset of human lymphocytes. Evidence that lymphokine-activated killer cells express this molecule and use it in their effector function.
Zocchi MR; Bottino C; Ferrini S; Moretta L; Moretta A
J Exp Med; 1987 Aug; 166(2):319-26. PubMed ID: 3598463
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic and functional analysis of human CD3+ and CD3- clones with "lymphokine-activated killer" (LAK) activity. Frequent occurrence of CD3+ LAK clones which produce interleukin-2.
Mingari MC; Ferrini S; Pende D; Bottino C; Prigione I; Moretta A; Moretta L
Int J Cancer; 1987 Oct; 40(4):495-8. PubMed ID: 3117711
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
Kaufmann Y; Levanon M; Davidsohn J; Ramot B
J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
[TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer cells. Analysis of progenitors and effectors.
Ortaldo JR; Mason A; Overton R
J Exp Med; 1986 Oct; 164(4):1193-205. PubMed ID: 3093626
[TBL] [Abstract][Full Text] [Related]
11. Functional characterization of human thymocytes: a limiting dilution analysis of precursors with proliferative and cytolytic activities.
Lopez-Botet M; Moretta L
J Immunol; 1985 Apr; 134(4):2299-304. PubMed ID: 3919089
[TBL] [Abstract][Full Text] [Related]
12. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity.
Ting CC; Hargrove ME; Yun YS
J Immunol; 1988 Aug; 141(3):741-8. PubMed ID: 3260909
[TBL] [Abstract][Full Text] [Related]
13. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
14. Clonal analysis of the involvement of T11 molecules in antigen receptor-mediated T lymphocyte functions.
Moretta A; Pantaleo G; Lopez-Botet M; Carrel S; Moretta L
Behring Inst Mitt; 1985 Aug; (77):39-47. PubMed ID: 2417584
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody.
Yun YS; Hargrove ME; Ting CC
J Immunol; 1988 Aug; 141(4):1390-7. PubMed ID: 3260924
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
17. Clonal analysis of T lymphocytes in spleens from patients with Hodgkin's disease. Frequent occurrence of unusual T4-positive cells which co-express cytolytic activity and production of interleukin-2.
Romagnani S; Maggi E; Parronchi P; Macchia D; Del Prete GF; Rossi-Ferrini PL; Ricci M; Moretta L
Int J Cancer; 1986 Mar; 37(3):343-9. PubMed ID: 3081452
[TBL] [Abstract][Full Text] [Related]
18. Both the precursors and the effectors of human lymphokine-activated killer (LAK) cells may belong to T lymphocytes.
Mingari MC; Pende D; Cozzani R; Merli A; Poggi A; Ferrini S; Moretta L
Ric Clin Lab; 1986; 16(3):437-41. PubMed ID: 3101157
[TBL] [Abstract][Full Text] [Related]
19. The role of interleukin 2 and T11 E rosette antigen in activation and proliferation of human NK clones.
Schmidt RE; Hercend T; Fox DA; Bensussan A; Bartley G; Daley JF; Schlossman SF; Reinherz EL; Ritz J
J Immunol; 1985 Jul; 135(1):672-8. PubMed ID: 3923116
[TBL] [Abstract][Full Text] [Related]
20. Functional surface structures on human natural killer cells.
Schmidt RE; Hercend T; Schlossman SF; Ritz J
Klin Wochenschr; 1985 Dec; 63(23):1189-200. PubMed ID: 2418257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
